Table 9 |
|||||||||
|
WOMAC scales inter-group comparisons |
|||||||||
|
Pain |
Stiffness |
Function |
|||||||
|
30 days |
60 days |
90 days |
30 days |
60 days |
90 days |
30 days |
60 days |
90 days |
|
|
|
|||||||||
|
UP446 500 mgs vs. UP446 250 mgs |
NS* |
NS |
0.038 |
NS |
NS |
NS |
NS |
NS |
NS |
|
UP446 250 mgs vs. CELECOXIB 200 mgs |
NS |
NS |
NS |
NS |
NS |
NS |
0.010 |
NS |
NS |
|
UP446 500 mgs vs. CELECOXIB 200 mgs |
0.020 |
NS |
NS |
NS |
NS |
NS |
0.015 |
0.043 |
0.039 |
|
UP446 250 mgs vs. PLACEBO |
NS |
NS |
NS |
0.000 |
0.027 |
0.015 |
0.010 |
0.043 |
0.039 |
|
UP446 500 mgs vs. PLACEBO |
0.044 |
0.032 |
0.001 |
0.001 |
NS |
0.005 |
0.015 |
0.016 |
0.003 |
|
CELECOXIB 200 mgs vs. PLACEBO |
NS |
0.009 |
NS |
0.023 |
NS |
NS |
0.015 |
0.016 |
0.003 |
|
|
|||||||||
|
*NS: Not statistically significant |
|||||||||
|
Sampalis and Brownell Nutrition Journal 2012 11:21 doi:10.1186/1475-2891-11-21 |
|||||||||
